Cancer
Malignant Liver Neoplasm
CI-CAN-00003177Explore in graph →
Top-level908 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003177Explore in graph →
Clinical trials
4,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (460)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06058663 | Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma | recruiting | Phase 1 | 16 | Mayo ClinicOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | recruiting | Phase 1 | 11 | Brian Henick, MDOTHER | 1 | May 13, 2026 | clinicaltrials |
| Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN(ELEGANCE) |
| recruiting |
| N/A |
| 60 |
| Nantes University HospitalOTHER |
| 1 |
| May 13, 2026 |
| clinicaltrials |
| NCT07012798 | FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07583316 | A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors | not yet recruiting | Phase 1 | 192 | Corregene Biotechnology Co., LtdINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07584018 | The DoHAICs Study Expansion Phase | not yet recruiting | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 13, 2026 | clinicaltrials |
| NCT07584317 | AI-Based Multimodal Integration for Tumor Microenvironment Analysis and Response Prediction in HCC Treated With TACE Plus Immunotherapy and Targeted Therapy (CHANCE2601) | not yet recruiting | — | 1,170 | Gao-jun TengOTHER | 0 | May 13, 2026 | clinicaltrials |
| NCT07081633 | Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma(TREMENDOUS-2) | active not recruiting | Phase 2 | 114 | AstraZenecaINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT07413354 | Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 94 | Tongji HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07580261 | YMN-A02 for Advanced Primary Hepatocellular Carcinoma. | not yet recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07582419 | Hybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment Decisions(HDL-CEUS-MRI) | not yet recruiting | — | 1,424 | The First Hospital of Jilin UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06794073 | Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study | recruiting | N/A | 17 | Shanghai Zhongshan HospitalOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07150624 | The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine | recruiting | Phase 4 | 96 | Anhui Provincial HospitalOTHER_GOV | 1 | May 11, 2026 | clinicaltrials |
| NCT07226869 | Computer Guided Microwave Liver Ablation(MWA Sim) | recruiting | N/A | 84 | NE Scientific INCINDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT06852820 | 68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC) | recruiting | Phase 2 | 10 | Melissa LumishOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07164313 | A Study of ZW251 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zymeworks BC Inc.INDUSTRY | 6 | May 7, 2026 | clinicaltrials |
| NCT01840592 | Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04657042 | 4D-MRI for Precision Medicine | recruiting | — | 100 | University of VirginiaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT07570849 | Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 35 | Shanghai Zhongshan HospitalOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03107416 | Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells | active not recruiting | Phase 1 / Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07014150 | Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma | recruiting | Phase 2 | 33 | Peking Union Medical College HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07122089 | Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis(IOSPHERE) | recruiting | Phase 2 | 80 | Center Eugene MarquisOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07226063 | Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer | not yet recruiting | Phase 2 | 16 | Amit MahipalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07568457 | Social Determinants of Health HCC Trial | not yet recruiting | N/A | 75 | University of Southern CaliforniaOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03482102 | Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer | active not recruiting | Phase 2 | 37 | Massachusetts General HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04478292 | A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy | recruiting | Phase 3 | 330 | Shanghai Children's Medical CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07565415 | Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy | not yet recruiting | Phase 2 | 88 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT02838836 | Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers | recruiting | — | 620 | University of Missouri-ColumbiaOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07322848 | DEB-TACE vs cTACE in HCC After TIPS(UPGRADE) | recruiting | Phase 3 | 206 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07478302 | A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 36 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07560488 | Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 43 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07560566 | SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin | recruiting | Phase 2 | 39 | National Taiwan University HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06519721 | Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC | active not recruiting | N/A | 12 | RenJi HospitalOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07075120 | Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer | recruiting | Phase 1 | 15 | University of HawaiiOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07558200 | Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors | not yet recruiting | Phase 1 | 138 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07138885 | A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma(DRIVE-II) | active not recruiting | Phase 2 | 62 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07556835 | Outcomes After Liver and Biliary Resection at a High-Volume Center(BILIVER) | not yet recruiting | — | 1,000 | Azienda USL Toscana CentroOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04483778 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 68 | Seattle Children's HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07274774 | SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma | recruiting | Phase 2 | 184 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07543783 | Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial | not yet recruiting | Phase 2 | 38 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Apr 28, 2026 | clinicaltrials |
| NCT07553767 | Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection | not yet recruiting | Early Phase 1 | 156 | Ningbo No.2 HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05440708 | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 193 | Tvardi Therapeutics, IncorporatedINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04856046 | Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer | active not recruiting | — | 36 | Mayo ClinicOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06045975 | Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure(DUMELEP) | active not recruiting | Phase 2 | 30 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07175441 | Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 220 | Riboscience, LLC.INDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07298577 | Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer(STOPHCC-GAAD) | enrolling by invitation | N/A | 2,100 | Siriraj HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07422753 | A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC | recruiting | Phase 2 | 36 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05655949 | Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio | recruiting | Phase 2 | 30 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07543510 | Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma | not yet recruiting | N/A | 38 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Apr 22, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 13, 2026source: clinicaltrials